EPS for Paratek Pharmaceuticals, Inc. (PRTK) Expected At $-1.05

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Logo
Investors sentiment decreased to 0.84 in Q2 2019. Its down 0.31, from 1.15 in 2019Q1. It is negative, as 12 investors sold Paratek Pharmaceuticals, Inc. shares while 25 reduced holdings. 10 funds opened positions while 21 raised stakes. 20.43 million shares or 5.63% less from 21.65 million shares in 2019Q1 were reported.
Northern Trust Corporation holds 0% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) or 414,364 shares. 96,253 were accumulated by Deutsche National Bank & Trust Ag. Lpl Limited Liability owns 60,063 shares or 0% of their US portfolio. Highland Cap L P accumulated 1.15M shares. The Ontario – Canada-based Bank & Trust Of Montreal Can has invested 0% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Water Island Cap Ltd Liability Corporation invested in 0.08% or 405,941 shares. Citigroup Inc holds 0% or 4,802 shares. Gabelli Funds Limited Co invested in 0% or 49,000 shares. Teton Advisors Incorporated reported 92,000 shares stake. Granahan Inv Mgmt Ma has invested 0.03% of its portfolio in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Brown Brothers Harriman And holds 287,902 shares. Roumell Asset Mngmt Ltd Liability Company, Maryland-based fund reported 678,795 shares. Alliancebernstein Limited Partnership holds 0% or 46,300 shares. Fortress Investment Grp Ltd Liability reported 0.19% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). 450,000 were accumulated by Rock Springs Cap Mngmt Limited Partnership.

Analysts expect Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) to report $-1.05 EPS on November, 5.They anticipate $0.04 EPS change or 3.96 % from last quarter’s $-1.01 EPS. After having $-1.02 EPS previously, Paratek Pharmaceuticals, Inc.’s analysts see 2.94 % EPS growth. The stock increased 2.08% or $0.08 during the last trading session, reaching $3.92. About 241,153 shares traded. Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has declined 67.54% since October 7, 2018 and is downtrending. It has underperformed by 67.54% the S&P500.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. The company has market cap of $127.54 million. The Company’s lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections , community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. It currently has negative earnings. The firm has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP.

More notable recent Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) news were published by: Globenewswire.com which released: “New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRAâ„¢ (Omadacycline) For Pneumonia and Skin Infections – GlobeNewswire” on February 06, 2019, also Seekingalpha.com with their article: “Paratek’s Nuzyra on par with linezolid in late-stage study – Seeking Alpha” published on August 30, 2019, Seekingalpha.com published: “Parateck finance chief bids adieu; shares down 4% – Seeking Alpha” on March 18, 2019. More interesting news about Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) were released by: Globenewswire.com and their article: “Paratek Pharmaceuticals Generates Net Revenues of $2.0 Million in the Second Quarter of 2019 – GlobeNewswire” published on August 06, 2019 as well as Gurufocus.com‘s news article titled: “Baupost’s Seth Klarman Dives Further Into Translate Bio – GuruFocus.com” with publication date: September 10, 2019.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.